Treatment Outcomes of Scleroderma with Janus Kinase Inhibitors: A Systematic Review

Scleroderma is a connective tissue disorder characterized by hardening and thickening of the skin. Initial treatment involves topical and systemic corticosteroid therapies, with immunosuppressive therapy in severe and refractory cases, although none are curative and outcomes are often poor. This review evaluates the efficacy and safety of novel Janus Kinase inhibitors (JAKi) therapy use in patients with cutaneous scleroderma.

硬化病是一种以皮肤硬化及增厚为特征的结缔组织疾病。初期治疗包括局部及全身性皮质类固醇疗法，对于严重且难治性病例，则采用免疫抑制剂治疗，尽管目前尚无根治方法，但预后通常不佳。本综述旨在评估新型雅各宾激酶抑制剂（JAKi）疗法在治疗皮肤硬化病患者的有效性和安全性。